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ABSTRACT 
Background L-DOPA is an amino acid precursor to the neurotransmitter dopamine that is 
extensively used as a prodrug for the treatment of Parkinson’s disease. However, L-DOPA is an 
unstable compound: when exposed to light or added to aqueous solutions, it may degrade, 
compromising its therapeutic properties.  
Research design and methods In this work, a new type of drug-loaded cyclodextrin-based 
nanosponge, obtained using molecular imprinting, is described for the prolonged and controlled 
release of L-DOPA. The molecularly imprinted nanosponges (MIP-NSs) were synthesized by cross-
linking -cyclodextrin with 1,1’-carbonyldiimidazole in DMF in the presence of L-DOPA as a 
template molecule. TGA, DSC and FTIR analyses were performed to characterize the interactions 
between L-DOPA and the two nanosponge structures. Quantitative NMR spectroscopy was used to 
determine the amount and the affinity of L-DOPA entrapped in the nanosponges. The in vitro L-
DOPA release kinetics from the NSs were quantitatively determined by HPLC analysis.  
Results The MIP-NSs show a slower and more prolonged release profile than the non-imprinted 
nanosponges. No degradation of the L-DOPA hosted in the MIP-NSs was observed after long-term 
storage at room temperature.  
Conclusions The MIP-NSs are a promising alternative for the storage and controlled delivery of L-
DOPA. 
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INTRODUCTION 
L-DOPA [(S)-2-amino-3-(3,4-dihydroxyphenyl) propanoic acid] is a non-proteinogenic amino acid, 
precursor to the neurotransmitter dopamine [1]. The lack of dopamine is at the base of Parkinson’s 
disease (PD), which afflicts approximately 0.3 % of the entire population, causing symptoms such as 
tremors, rigidity, bradykinesia and akinesia [2]. The administration of dopamine is completely 
ineffective as a treatment for PD because dopamine is not able to cross the blood-brain barrier, while 
L-DOPA can reach the central nervous system and be converted, via decarboxylation [3,4] by the 
neuronal amino acid decarboxylase, into dopamine. More exactly, L-DOPA acts as a prodrug that is 
absorbed in the small intestine and carried to the brain by the blood stream.  
L-DOPA is currently the most widely used drug for the treatment of PD. However, it is an unstable 
compound; when exposed to light or added to aqueous solution (especially basic solution), it may 
degrade, compromising its therapeutic properties. Approximately 99 % of orally administered L-
DOPA is degraded through peripheral decarboxylation and oxidation [5,6]. The remaining 1 % can 
reaches the brain unchanged. To reduce the peripheral conversion of this drug into dopamine, 
carbidopa and benserazide are usually added to the drug formulation as inhibitors of the 
decarboxylase activity [1-6]. 
Additionally, it is not possible to reach and maintain a constant L-DOPA plasma concentration via 
oral administration of conventional immediate-release systems because the concentration fluctuates 
widely with time [7]. Consequently, it is difficult to control the symptoms of PD and allow patients 
to achieve a satisfying quality of life.  
Many other administration routes have been explored to stabilize the L-DOPA concentration in the 
blood. Good results have been obtained with intravenous [8] and intra-duodenal infusions of L-DOPA 
[9]; however, these treatments are time-consuming and continuous medical assistance is required.  
The implantation of long-term L-DOPA releasing systems has also been investigated [10]. However, 
despite the positive results, implantation remains an invasive and problematic technique. 
Transdermal delivery systems represent an interesting and easy alternative that could provide long-
term sustained release of the drug. Since L-DOPA is a polar compound, it cannot easily cross the 
lipid barrier of the skin; therefore, organic solvents have been employed to increase the cutaneous 
permeability of the drug. Studies conducted on rats have been successful, but the effects of these 
dermal treatments on humans are still unknown [11]. Encouraging results have also been achieved 
using gastroretentive delivery systems. Since L-DOPA is mostly absorbed in the first part of the small 
intestine (duodenum), gastroretentive delivery systems have been developed with the aim of 
prolonging the release of the drug in the area of maximal absorbance. Studies have not yet been 
performed in humans [12]. Odak et al. used highly soluble hydroxypropylated -cyclodextrin to form 
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stable complexes with L-DOPA. The stability, aqueous solubility and consequently the 
bioavailability of the drug were increased [13]. The use of microscopic and nanoscopic carriers as 
drug delivery systems is one of the most promising approaches to both achieving a constant L-DOPA 
plasma concentration and reducing drug degradation. Microspheres, nanoparticles and liposomes 
have been exploited [14].  
Biodegradable polymers have been employed to fabricate microspheres to encapsulate L-DOPA. 
These systems provide prolonged release of the drug thanks to two simultaneous, slow processes: the 
diffusion of the drug through the pores of the microsphere and polymer degradation [15]. More 
recently, molecularly imprinted polymers (MIPs) have been proposed as a new drug delivery 
technology to achieve controlled and sustained release systems [16]. In contrast to polymer drug 
conjugates, where the drug is generally covalently bound to the polymer, drugs in MIPs are hosted 
through non-covalent interactions. MIPs based on cyclodextrins (CDs) have been reported in the 
literature [17]. The presence of CDs within an imprinted polymer network can improve the 
performance of the MIP [18]. Furthermore CDs can be used as pore templates to form nanoporous 
materials due to their peculiar structure and the ability to form inclusion complexes [19]. Indeed, they 
are cyclic oligosaccharides that exhibit a truncated cone shape structure with an interior hydrophobic 
cavity and a hydrophilic exterior site due to the presence of hydroxyl groups. Multiple approaches 
have been proposed to obtain MIPs based on CDs. For example, acryloyl-CD monomers can undergo 
radical polymerization to obtain the corresponding MIP. Condensation polymerization is less likely 
or limited to un-reactive template drugs [20].  
Because of the large amount of reactive hydroxyl groups, CDs can act as polyfunctional monomers 
and be cross-linked using a wide variety of chemicals bearing two or more functionalities (e.g., 
dianhydrides, diisocyanates, epoxides, and dicarboxylic acids), producing insoluble, 3-dimensional 
polymers called “nanosponges” (NSs). The final properties of a CD-NS are strongly influenced by 
the nature of the cross-linker, the degree of cross-linking and the conditions of the synthesis reaction 
[21]. Several studies on the formulation and use of CD-NSs as nanocarriers have been conducted, 
showing that CD-NSs are a suitable delivery system for drugs, macromolecules and gases [22-29]. 
Shende et al. reported on the acute and repeated dose toxicity in animals of orally administered -
CD-NSs prepared using three types of cross-linker, i.e., pyromellitic dianhydride, 1,1’-
carbonyldiimidazole and hexamethylene diisocyanate. In accordance with OECD guidelines 423 and 
407, all formulations were proved to be safe at the tested concentrations of 2000 mg/kg and 300 
mg/kg for acute and repeated dose toxicity, respectively [30]. Recently, molecularly imprinted NSs 
have been developed as biomimetic systems to evaluate blood glucose. The synthesis procedure used 
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pyromellitic dianhydride and glucose phosphate as the cross-linker and template molecule, 
respectively [31]. 
Based on NMR studies and predictive modelling previously reported in the literature [32, 33] for the 
ability of -CD to form inclusion complexes with L-DOPA, -CD was selected as the building block 
monomer for the preparation of a new L-DOPA delivery system. More specifically, in this work, 
polycarbonate -CD-based NSs were obtained by cross-linking -CD with 1,1’-carbonyldiimidazole. 
This reaction was conducted in the presence of highly reactive and unstable L-DOPA molecules to 
obtain a molecularly imprinted nanosponge (MIP-NS). 
To the best of our knowledge, this is the first report of CD-NSs applied to the study of an oral 
formulation for the delivery of a drug for the treatment of a neurodegenerative disease. 
 
MATERIALS AND METHODS 
Materials 
L-DOPA, 1,1’-carbonyldiimidazole (CDI), anhydrous N,N-dimethylformamide (DMF) and other 
reagents of analytical grade were purchased from Sigma-Aldrich (Saint Louis, MO, USA). -
cyclodextrin (-CD) was a generous gift of Roquette Italia (Cassano Spinola-Italy) and was dried in 
oven at 120 °C to constant weight before use. DMF was dried immediately prior to use by the addition 
of CaH2.  
 
Synthesis of molecularly imprinted nanosponges  
Molecularly imprinted nanosponges (MIP-NSs) were synthesized by reacting -CD with different 
amounts of 1,1’-carbonyldiimidazole (CDI) in the presence of a variable amount of drug (2 % and 10 
% with respect to the moles of CD). A schematic representation of the preparation of a MIP-NS is 
depicted in Figure 1. 
Briefly, to obtain MIP-NSs, anhydrous -CD (mmoles are reported in Table 1) was dissolved, under 
vigorous stirring, in anhydrous N,N-dimethylformamide (DMF); then, L-DOPA was added. Finally, 
the required amount of CDI was introduced, and the reaction was allowed to react at 60 °C for 4 hours 
and at 90 °C for an additional 3 hours under a nitrogen atmosphere and protecting the reaction vessel 
from light by covering with aluminium foil. Four MIP-NSs were obtained by changing the amount 
of L-DOPA and the CDI/β-CD ratio, (Table 1. The numbers in brackets indicate the molar ratio 
between -CD and the cross-linker). 
When the reaction was completed, the monolithic block was crushed, treated with excess acetone and 
filtered under vacuum. The solid was extensively washed with acetone to remove DMF, imidazole 
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and possible unreacted monomers but not the drug (L-DOPA is almost insoluble in acetone). The L-
DOPA-loaded NSs were then stored in hermetic vials that were protected from light. 
For comparison, polycarbonate non-imprinted nanosponges (NIP-NSs) with two cross-linking 
degrees were synthesized in the same way but omitting L-DOPA. Successively, each  type of NIP-
NS in aqueous suspension (10 mg/mL) was loaded with L-DOPA. For this purpose, 6 mg of L-DOPA 
were added to 3 mL of each NIP-NS aqueous suspension and incubated at r.t. for 24 h under mild 
stirring. The loaded NIP-NSs (L-NIP-NSs) were recovered through centrifugation and were freeze-
dried. 
The re-loading properties of the MIP-NSs were evaluated by complete removal of L-DOPA via 
Soxhlet extraction in ethanol and water (50:50 v/v) and subsequent adsorption from an L-DOPA 
solution at room temperature for 24 hours. For comparison, a similar procedure was followed for the 
NIP-NSs. 
 
L-DOPA quantitative determination 
The quantitative determination of L-DOPA was performed by HPLC using a Perkin Elmer instrument 
(L2 Binary Pump, Perkin Elmer) with a UV-Vis spectrophotometer detector (LC 95, Perkin Elmer, 
USA) using an external standard method. A reverse-phase Hypersil ODS column (25 cm x 4.6 mm 
Varian, USA) was used with a mobile phase consisting of 980 mL of water, 16.5 g of sodium 
dihydrogen orthophosphate, 20 mL of methanol, 1 mL of 0.1 M EDTA and 1.2 mL of 0.5 mM sodium 
heptanesulphonate. The pH of the solution was adjusted to 3.4 with 1 M orthophosphoric acid. The 
analyses were performed at a flow rate of 0.9 mL/min at room temperature using a UV detector at 
280 nm. 
 
Nanosponge characterization  
Fourier transform infrared (FTIR) spectra were recorded in the spectral range of 4000-650 cm-1 using 
a Perkin Elmer Spectrum 100 instrument in the attenuated total reflectance (ATR) mode with a 
diamond crystal using 32 scans per spectrum and a resolution of 4 cm-1. 
The surface morphology of the NIP-NSs and MIP-NSs was observed by field-emission scanning 
electron microscopy (FESEM, JEOL-JSM-6700F). The samples were examined after metallization 
with gold using the following experimental parameters: WD = 3.3 mm, EHT = 5.00 kV, and probe 
current = 130 pA. 
Thermogravimetric analyses (TGA) were conducted on a TGA 2050 model from TA Instruments by 
heating samples contained in alumina pans at 10 °C/min from 40 to 700 °C in a nitrogen flow. 
Differential scanning calorimetry (DSC) was performed using a Perkin Elmer DSC/7 (Perkin Elmer, 
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CT, USA) equipped with a TAC 7/DX instrument controller. A heating rate of 10 °C/min was used 
in the 25–300 °C temperature range. Standard aluminium sample pans (Perkin Elmer) were used; an 
empty pan was used as the reference standard. Analyses were performed in triplicate on 5 mg samples 
under a nitrogen flow. 
 
NMR studies 
For NMR spectroscopy, one equivalent of β-CD was added to a sample containing 10 mM L-DOPA 
solution for the complexation study. For the kinetics study, three samples were prepared using 0.7 
mL of a stock solution of L-DOPA (10 mM) in D2O. One sample was used as the concentration 
reference; the two other samples contained empty MIP(1:8) (obtained from the sample 
MIP(1:8)+10%L-DOPA, after complete removal of L-DOPA) and NIP(1:8), with one equivalent of 
β-CD. At absorption equilibrium, which occurred within 24 hours of sample preparation, additional 
equivalents of polymer (up to five equivalents) were introduced. Quantitative 1H spectra were 
recorded immediately after each addition of β-CD and for the following 24 hours. All samples were 
stored at room temperature away from light sources. 
NMR measurements were performed on a spectrometer operating at 600 MHz for 1H nuclei. The 
temperature was controlled to ±0.1 °C. For quantitative measurements, a 15 s pulse delay was 
selected. The 2D ROESY (rotating-frame Overhauser enhancement spectroscopy) experiments were 
performed using a mixing time of 0.3 or 0.6 s. The pulse delay was maintained at 5 s; 256 increments 
of 8 scans and 2K data points were collected for each spectrum. DOSY (diffusion ordered 
spectroscopy) experiments were conducted using a stimulated echo sequence with self-compensating 
gradient schemes, a spectral width of 6000 Hz and 64K data points. Typically, a value of 40 ms was 
used for , 2 ms for , and g was varied in 20 steps (4 transients each) to obtain an approximately 90-
95 % decrease in the resonance intensity at the largest gradient amplitude. The baselines of all arrayed 
spectra were corrected prior to processing the data. After data acquisition, each FID was apodized 
with 1.0 Hz line broadening and was then Fourier transformed. The data were processed with the 
DOSY macro (including the determination of the resonance heights of all signals above a pre-
established threshold and the fitting of the decay curve for each resonance to a Gaussian function) to 
obtain pseudo two-dimensional spectra with NMR chemical shifts along one axis and calculated 
diffusion coefficients along the other. The gradient amplitudes in the DOSY experiments were 
calibrated using a standard sample of 99 % D2O. 
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Determination of the size, polydispersity index and zeta potential of the nanosponges 
The sizes and polydispersity indices of the two types of NSs were determined by dynamic light 
scattering using a 90 Plus particle sizer (Brookhaven Instruments Corporation, USA) equipped with 
MAS OPTION particle sizing software. The measurements were performed at a fixed scattering angle 
of 90° and at 25 °C. The samples were suitably diluted with filtered distilled water before each 
measurement. Zeta potential measurements were made using an additional electrode in the same 
instrument. For the zeta potential determination, the NS formulations were diluted with 0.1 mM KCl 
and placed in the electrophoretic cell, and an electric field of approximately 15 V/cm was applied. 
 
L-DOPA stability studies 
Stability studies on L-DOPA in solution were conducted spectrophotometrically. UV-Vis spectra 
were acquired with a Lambda 25 UV-Vis spectrophotometer (Perkin Elmer). Four solutions with 
different pH values, i.e., 2, 4, 7 and 9, were prepared by adding HCl or NaOH to ultrapure water; 
then, L-DOPA was introduced at a concentration of ~10-5 M. The spectra were collected between 200 
and 800 nm after 10 minutes, 8 hours, 1, 2, 4, 8, and 16 days and were then overlaid. To evaluate the 
stability of the drug encapsulated in the NS, a freeze-dried sample was weighed, extracted and then 
centrifuged. After dilution of the supernatant, the solution was injected into the HPLC system for the 
quantitative determination. 
 
Determination of the L-DOPA content in the nanosponges  
A weighed amount (5 mg) of all types of L-DOPA-loaded NSs was dispersed in ultrapure water, 
sonicated for 30 min and then diluted with the HPLC mobile phase. After centrifugation, the 
supernatant was diluted and analysed by HPLC, as described before, to determine the drug 
concentration. The encapsulation efficiency and drug loading capacity were calculated using the 
following equations: 
 
Encapsulation efficiency = 
Actual amount of L−DOPA loaded in NSs
Theoretical amount of drug loaded NSs
 x 100 
Loading capacity = 
Actual amount of L−DOPA loaded in NSs
L−DOPA loaded nanosponges weight
 x 100 
 
In vitro release study  
The in vitro release studies of NS-encapsulated L-DOPA from MIP-NSs and NIP-NSs were 
conducted in phosphate buffer at pH 6.0 and pH 7.4 using multi-compartment rotating cells with a 
dialysis membrane (Sartorius, cut off: 12,000-14,000 Da). The donor phase consisted of an aqueous 
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NS suspension containing a fixed amount of L-DOPA. The receiving phase, which consisted of 
phosphate buffer at pH 6.0 or pH 7.4, was completely withdrawn and replaced with fresh medium at 
fixed time intervals. The experiment was performed in triplicate. 
The concentration of L-DOPA released to the receiving phase was monitored for 48 hours using the 
HPLC method described above. 
 
RESULTS AND DISCUSSION 
 
Study of the stability of L-DOPA 
Since the stability of L-DOPA is a critical issue for formulation studies, investigation of the chemical 
stability of L-DOPA to oxidation in aqueous solutions at different pH values was conducted by UV-
Vis spectroscopy. The results are reported in Figure 2. In acidic solution (pH 2 and 4), all L-DOPA 
spectra were perfectly overlaid; no changes were observed over time. In the neutral solution, the 
initial degradation process became visible after 1 day. In basic solution (pH 9), 8 hours were sufficient 
to generate a detectable amount of oxidized L-DOPA. The characteristic absorption peak of L-DOPA 
appears at ~280 nm. The chemical species generated from the oxidation of L-DOPA [34] absorb all 
wavelengths from 200 to 800 nm, producing a dark brown solution. In particular, the main absorption 
peak of dopachrome is at ~475 nm.  
The evidence of the low stability of L-DOPA in both alkaline and neutral environments, which was 
confirmed by the UV-Vis study, allowed us to better appreciate and note the protective effect of the 
NSs in aqueous media, as will be explained in the release study section. 
The thermal stability of L-DOPA was investigated using thermogravimetric and infrared 
spectroscopic analyses. The TGA curve of L-DOPA is shown in Figure 3a. The weight of L-DOPA 
is constant up to 280 °C. Additionally, ATR-FTIR analyses of the drug before and after heat treatment 
similar to the one performed during the synthesis reaction (i.e., an isotherm at 60 °C for 4 hours, 
followed by a second isotherm at 90 °C for 3 hours in N2) were performed. The two spectra are shown 
in Figure 3b, with perfect agreement between the two profiles. Therefore, according to TGA and 
ATR-FTIR analyses, L-DOPA is not affected by the thermal treatments used during the synthesis of 
MIP-NSs. 
Previous experiments evaluated the chemical and thermal stability of L-DOPA, but the introduction 
of L-DOPA during the synthesis step is potentially detrimental to drug encapsulation in the polymer 
structure. Since L-DOPA carries a number of functional groups (i.e., -OH, -COOH, -NH2) that can 
easily react with the cross-linker, modification of L-DOPA would be expected. Preliminary 
experiments confirmed that when CDI is added to a solution of L-DOPA in DMF, a cross-linked 
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insoluble polymer is obtained, even at room temperature (Figure 4a). Surprisingly, the HPLC analysis 
demonstrated that a negligible amount of L-DOPA (less than 0.5 wt %) was damaged during the 
polymerization reaction in the presence of -CD. L-DOPA was extracted from the MIP-NSs and 
analysed by HPLC to determine the impact of the reaction at the molecular level. The interaction with 
MIP-NSs prevented the degradation of the drug. The chromatographic peak of the extracted L-DOPA 
showed the same retention time as that of the pure drug, which was used as a standard reference 
(Figure 4b). Moreover, no degradation products, which are easily detectable in the HPLC 
chromatograms of L-DOPA under stress conditions [34], were observed. In addition, the results are 
in agreement with the quantitative determination of the drug. Therefore, protective action of -CD on 
L-DOPA during the synthesis reactions through the formation of inclusion complexes can be 
hypothesized. 
To support this statement, DSC analyses were performed on MIP-NSs and showed the disappearance 
of the melting peak signal of L-DOPA at 310 °C. This behaviour can be ascribed to the molecular 
association of the drug with the NS structure (data not shown). 
The affinity of L-DOPA for the CD cavity was investigated. Information about the complexing 
efficiency of β-CD in solution was obtained by analysing the translational diffusion coefficient D 
through DOSY experiments [35]. The diffusion coefficient is inversely proportional to the 
hydrodynamic radius (rH), according to the Stokes-Einstein equation (Eq. 1): 
 
D = kT/(6πηrH)                   (1) 
 
where k is the Boltzmann constant, T is the absolute temperature, and η is the dynamic viscosity of 
the solution. 
Since complexation leads to an increase in the apparent molecular size, variations in the diffusion 
coefficients are strictly related to aggregation phenomena. In fast exchange conditions, the observed 
diffusion coefficient for a given species (Dobs) is determined by the weighted average between the 
diffusion coefficient of the free molecule (Df) and the diffusion coefficient of the molecule in the 
bound state (Db), as shown in Eq. 2: 
 
Dobs = xfDf  + xbDb        (2) 
 
where xb and xf are the molar fractions in the bound and free state, respectively. 
When the molecular size of the host is significantly larger than the complexed substrate, Db can be 
approximated by the translational diffusion coefficient of the complexing agent (DC); hence, the 
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molar fraction of the complexed substrate in the bound state can be estimated using a single point 
determination (Eq. 3) [36], avoiding time-consuming titration experiments. 
 
xb = (Dobs - Df)/(DC - Df)       (3)  
 
For the chemical shift, there was no change in the proton frequency of the two molecules in the 
mixture sample compared with the pure compounds. Nevertheless, the variation in the diffusion 
coefficients indicate that inclusion complexation occurs (Table 2). A diffusion coefficient of 5.2 x 10-
10 m2s-1 was measured for pure L-DOPA, which only slightly decreased to 4.9 x 10-10 m2s-1 in the 
presence of five equivalents of β-CD. Using the single point determination, we gave a rough estimate 
of the amount of L-DOPA complexed with β-CD, which was approximately 10 %. 
The complexation stereochemistry was analysed by the ROESY experiment (Figure 5a); there were 
some dipolar correlations between protons H5 and H3 inside the cavity of β-CD and the aromatic 
protons of L-DOPA.  
In particular, the H5 and H6 nuclei, which are located near the smaller opening of β-CD, interact with 
L-DOPA Hd and, in a minor way, with He. In contrast, the H3 protons, which can be found near the 
larger opening of β-CD, have ROE effects with He and, to a slightly lesser extent, with Hc. No other 
intermolecular ROE correlations were found. 
The recorded effects are consistent with the inclusion of the aromatic moiety of L-DOPA in the 
lipophilic cavity of the β-CD, as reported in Figure 5b, thus explaining the reduced reactivity of L-
DOPA towards CDI and the preservation of its structure during polymerization. 
 
Characterization of MIP-NSs 
The presence of L-DOPA in the MIP-NSs structure was confirmed by ATR-FTIR analysis. In the 
infrared spectra of the four polycarbonate MIP-NSs (Figure 6), there is a characteristic peak due to 
the absorption of C=C in tri-substituted aromatic rings at ~1532 cm-1. This peak does not appear in 
the IR spectra of the plain NSs used as reference. Because of the low concentrations of L-DOPA 
introduced during the synthesis step, any additional absorption peaks of L-DOPA are covered by the 
absorption bands of the NS. 
The formulations containing the lowest amount of L-DOPA (2 %) were smaller (approximately 15 
%) than those of MIPs containing 10 % L-DOPA (Table 3). The size difference might indicate a 
greater amount of L-DOPA associated with the polymer network. This behaviour is in agreement 
with the encapsulation efficiency results (Table 3). All MIP-NSs showed good ability to load L-
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DOPA, with an encapsulation efficiency greater than 95 %. Moreover, the loading capacity of MIP-
NSs is between 8 and 14 %. All the MIP-NSs showed greater encapsulation capacity than NIP-NSs. 
The lower zeta potential values of the MIP-NSs than those of the NIP-NSs is further experimental 
evidence of the different structural interaction (network) between the two polymer matrices and the 
effective interaction of the drug with the polymer matrices (Table 3). 
The FESEM images shown in Figure 7 show no relevant differences in the morphology of the MIP 
and NIP-NSs. 
The superior ability of empty MIP-NSs obtained from MIP-NSs after complete removal of L-DOPA 
to recognize and encapsulate L-DOPA in comparison with NIP-NSs was supported by NMR analysis. 
The quantitative NMR spectrum of the reference sample was recorded immediately after its 
preparation; quantitative spectra of the samples in the presence of the polymers were recorded within 
24-72 hours after the addition of the polymers to ensure equilibrium and maximum absorption. Figure 
8a shows the L-DOPA absorption percentage as a function of the amount of each type of NS. There 
is an almost linear correlation of the encapsulation extent for both polymers. The absorption of the 
substrate roughly doubles in the presence of the imprinted NS, with respect to the non-imprinted NS. 
By adding polymer containing 5 equivalents of β-CD, approximately 41 % of the L-DOPA was 
absorbed by the imprinted polymer, whereas barely 20 % was absorbed by the NIP, proving the 
effective molecular recognition of empty MIP-NSs towards L-DOPA. 
 
L-DOPA in vitro release study from MIP-NSs 
L-DOPA was released from all types of MIP-NSs with slow and biphasic kinetics over an extended 
period of time. Figure 8b shows the in vitro release profiles of encapsulated 10 % L-DOPA from 
MIP(1:4) and MIP(1:8). After 48 hours, they released 52.6 % and 56.8 % of the drug. Approximately 
32 % of the drug was released by MIP(1:8)+10%L-DOPA after 6 hours, while only 26 % was released 
for the other type of MIP-NS (see the upper panel in Figure 8b), with no initial burst effects. The 
absence of an initial burst effect indicated that the drug is not adsorbed on the NS surface but strongly 
interacts with the NS structure. Pseudo zero-order kinetics were observed up to 4 h. 
The modification of the crosslinker-CD ratio produced changes in the drug release patterns due to the 
different network structure. The MIP(1:4)+2%L-DOPA and MIP(1:8)+2%L-DOPA had slower 
release kinetics than the other two types of MIP-NSs. After 48 hours, MIP(1:4)+2%L-DOPA and 
MIP(1:8)+2%L-DOPA released only 30 % of the total amount of encapsulated drug (data not shown), 
while MIP(1:4)+10%L-DOPA and MIP(1:8)+10%L-DOPA released more than 50 %. This difference 
might be ascribed to the better fit of the L-DOPA molecule within the MIP-NS structure at low 
concentrations. 
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The release kinetics of L-DOPA from L-NIP-NSs were faster than from MIP-NSs, indicating a 
different type of association within the polymer nanostructures (data not shown). 
Figure 8c shows the in vitro release profiles of MIP(1:4)+10%L-DOPA and NIP(1:4)+10%L-DOPA 
for comparison purposes. The L-DOPA release kinetics were faster from L-NIP-NSs than from the 
corresponding molecularly imprinted NSs. After 4 hours, MIP-NSs released approximately 21 % of 
the total amount of encapsulated drug, while L-NIP-NSs released approximately 77 %. No initial 
burst effects were observed for either formulation, indicating the good encapsulation of the drug. The 
inclusion of L-DOPA as a template during the synthesis favoured stronger interactions of the drug 
with the polymer structure and CD cavities, resulting in a slower and more prolonged release profile 
than L-NIP-NSs. The controlled and sustained kinetic behaviour might contribute to preventing 
critical oscillations in the L-DOPA plasma concentration. 
 
CONCLUSIONS 
New MIP-NSs for L-DOPA delivery were successfully synthesized using the drug as a template. 
Good encapsulation efficiencies and drug loading capacities were achieved. The protective effect of 
the NSs on L-DOPA molecules, which is due to the molecular interactions between L-DOPA and the 
polymer structure and the formation of inclusion complexes with the CD units, was highlighted during 
synthesis and storage. FTIR and thermal analyses confirmed the presence of the drug inside the NS 
structure after washing. Moreover, the NMR results showed that there is an inclusion of the aromatic 
moiety of L-DOPA in the cavity of the CD, which might be the reason for the effective performance 
of this molecularly imprinted drug delivery system. The in vitro studies indicated slow and controlled 
release kinetics over time, confirming that the MIPs have a strong ability to store the drug and sustain 
its release. 
Based on these results, polycarbonate β-CD-based MIP-NSs are a promising new drug delivery 
system for the protection and prolonged release of L-DOPA for oral administration. 
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CAPTIONS 
 
Figure 1. Schematic representation of the synthesis of a MIP-NS. 
 
Figure 2. UV-Vis spectra of L-DOPA solutions at 4 pH values: 2, 4, 7 and 9. The spectra collected 
after 10 minutes, 8 hours, 1, 2, 4, 8 and 16 days are overlaid in the 4 plots. 
 
Figure 3. a) TGA of L-DOPA, programme used: equilibrium at 40°C, increase at 10°C/min to 700°C 
in N2. b) ATR-FTIR analysis of L-DOPA (blue line) and L-DOPA after heating in TGA under a 
nitrogen flow at 60 °C for 4 hours and at 90 °C for an additional three hours (red line). 
 
Figure 4. a) Cross-linked insoluble polymer obtained by reacting 1 g of L-DOPA with 1.644 g of 
CDI in 4 ml of anhydrous DMF at room temperature. The gelation point was reached after 1 day. b) 
HPLC analyses of L-DOPA. On the left: standard L-DOPA solution; on the right: L-DOPA extracted 
from MIP(1:4)+10% L-DOPA. 
 
Figure 5. a) ROESY experiment results. b) Schematic representation of β-CD interaction with L-
DOPA. 
 
Figure 6. a) ATR-FTIR analysis of the L-DOPA-loaded NSs (red lines) compared with the plain NSs 
(blue lines). b) ATR-FTIR analysis of the L-DOPA free drug. 
 
Figure 7. FESEM images of a) NIP(1:4) and b) MIP(1:4)+10%L-DOPA. Magnification 25 K. 
 
Figure 8. a) L-DOPA adsorption percentage in empty MIP(1:8)+10%L-DOPA and NIP(1:8) NSs 
obtained by NMR. b) In vitro release profile of L-DOPA from the two types of MIP+10%L-DOPA 
NSs over time. c) In vitro release profile of L-DOPA from MIP(1:4) and L-NIP(1:4) NSs loaded with 
10% L-DOPA. 
 
Table 1. Qualitative and quantitative composition of reactants used in each NS synthesis. The 
numbers in brackets indicate the molar ratio of β-CD:cross-linker. 
 
Table 2. Diffusion coefficients (D, x1010 m2s-1) of β-CD and L-DOPA (5:1, [L-DOPA] = 10 mM) in 
the β-CD/L-DOPA mixture compared with pure compounds. 
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Table 3. Average size, polydispersity indices, zeta potential and encapsulation efficiency values of 
all types of MIP-NSs. 
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FIGURE 2 
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FIGURE 3 
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FIGURE 4 
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a) 
 
 
                                                         b)  
 
FIGURE 6 
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FIGURE 7 
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FIGURE 8 
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TABLE 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nanosponge Samples 
DMF 
(ml) 
-CD 
(mmol) 
L-DOPA 
(mmol) 
CDI 
(mmol) 
NIP(1:4) 60 8.81 - 35.24 
NIP(1:8) 60 8.81 - 70.48 
MIP(1:4)+2%L-DOPA 60 8.81 0.18 35.24 
MIP(1:8)+2%L-DOPA 60 8.81 0.18 70.48 
MIP(1:4)+10%L-DOPA 60 8.81 0.88 35.24 
MIP(1:8)+10%L-DOPA 60 8.81 0.88 70.48 
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Sample Dβ-CD DL-DOPA 
β-CD 3.0 - 
L-DOPA - 5.2 
β-CD/L-DOPA 2.7 4.9 
 
TABLE 2 
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TABLE 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nanosponge Sample 
Average size 
(nm) 
Polydispersity 
index 
Z-Potential 
(mV) 
Encapsulation 
Efficiency (%) 
MIP(1:4)+2%L-DOPA 346.3 ± 6.4 0.207 ± 0.021 -12.26 ± 1.27 95.2 
MIP(1:8)+2%L-DOPA 374.7 ± 8.2 0.215 ± 0.018 -11.4 ± 1.32 95.6 
MIP(1:4)+10%L-DOPA 411.6 ± 7.7 0.221 ± 0.015 -14.20 ± 1.03 97.8 
MIP(1:8)+10%L-DOPA 421.2 ± 9.3 0.203 ± 0.013 -22.3 ± 1.05 98.2 
NIP(1:4) 356.5 ± 5.3 0.204 ± 0.022 -25.74 ± 0.36 90.5 
NIP(1:8) 381.7 ± 10.6 0.214 ± 0.014 -26.21 ± 1.09 82.1 
